This data-based cohort consisted of 26,508 (7%) United States veterans out of the 399,290 who tested positive for SARS-CoV-2 from 1 March to 10 September 2020. We aimed to assess the interaction of post-index vitamin D (Vit D) and corticosteroid (CRT) use on 30-day mortality among hospitalized and non-hospitalized patients with coronavirus disease 2019 (COVID-19). Combination Vit D and CRT drug use was assessed according to four multinomial pairs (−|+, −|−, +|+, +|−). Respective categorical effects were computed on a log-binomial scale as adjusted relative risk (aRR). Approximately 6% of veterans who tested positive for SARS-CoV-2 died within 30 days of their index date. Among hospitalized patients, a significantly decreased aRR was observed for the use of Vit D in the absence of CRTs relative to patients who received CRTs but not Vit D (aRR = 0.30; multiplicity corrected, p = 0.0004). Among patients receiving systemically administered CRTs (e.g., dexamethasone), the use of Vit D was associated with fewer deaths in hospitalized patients (aRR = 0.51) compared with non-hospitalized patients (aRR = 2.5) (P-for-Interaction = 0.0071). Evaluating the effect of modification of these compounds in the context of hospitalization may aid in the management of COVID-19 and provide a better understanding of the pathophysiological mechanisms underlying this and future infectious disease outbreaks.
Background: We performed an observational Veterans Health Administration cohort analysis to assess how risk factors affect 30-day mortality in SARS-CoV-2-infected subjects relative to those uninfected. While the risk factors for coronavirus disease 2019 (COVID-19) have been extensively studied, these have been seldom compared with uninfected referents. Methods: We analyzed 341,166 White/Black male veterans tested for SARS-CoV-2 from March 1 to September 10, 2020. The relative risk of 30-day mortality was computed for age, race, ethnicity, BMI, smoking status, and alcohol use disorder in infected and uninfected subjects separately. The difference in relative risk was then evaluated between infected and uninfected subjects. All the analyses were performed considering clinical confounders. Results: In this cohort, 7% were SARS-CoV-2-positive. Age >60 and overweight/obesity were associated with a dose-related increased mortality risk among infected patients relative to those uninfected. In contrast, relative to never smoking, current smoking was associated with a decreased mortality among infected and an increased mortality in uninfected, yielding a reduced mortality risk among infected relative to uninfected. Alcohol use disorder was also associated with decreased mortality risk in infected relative to the uninfected. Conclusions: Age, BMI, smoking, and alcohol use disorder affect 30-day mortality in SARS-CoV-2-infected subjects differently from uninfected referents. Advanced age and overweight/obesity were associated with increased mortality risk among infected men, while current smoking and alcohol use disorder were associated with lower mortality risk among infected men, when compared with those uninfected.
24 September 2025 in JNCI: Journal of the National Cancer Institute
Background: Despite the importance of clinical trials in the advancement of cancer treatments, there are barriers to participant enrollment. Decentralized clinical trials are conducted at a different physical location than where patients receive medical care and can address patient-level and institution-level barriers that affect participant enrollment. Methods: The Veterans Health Administration (VA) created a cancer-focused decentralized clinical trial program with a dedicated research team, operational manual, and other standardized operational protocols to support trial conduct. The decentralized clinical trial program works closely with the VA Office of Research & Development and VA central institutional review board. Results: Ten cancer decentralized clinical trials have been implemented: 2 observational, 5 nontherapeutic interventional, and 3 therapeutic interventional. Eight were implemented as fully remote decentralized clinical trials, and 2 were hybrid decentralized clinical trials, with hybrid requiring collaboration with local clinicians for nonresearch activities. Across 47 VA medical centers, 134 Veterans enrolled: 31 (23%) in observational, 99 (74%) in nontherapeutic interventional, and 4 (3%) in therapeutic interventional decentralized clinical trials. Demographic characteristics of enrolled participants mirrored that of Veterans receiving cancer care through the VA’s National TeleOncology service, including rurality (31%) and non-White minority status (19%). Examples of the methods for research conduct that have been used across these decentralized clinical trials are included. Conclusions: Cancer decentralized clinical trials can address barriers to participant enrollment, but not every clinical trial can be conducted in a decentralized manner. By sharing experiences regarding the conduct of cancer decentralized clinical trials in the VA, research sponsors, regulatory authorities, and other research groups can more readily and widely implement these trials.